Ixaka is a private UK-based cell and gene therapy company with operations in the UK, Spain and France.  The company is focused on the natural power of the body to cure disease.

Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action.

Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.

Biotechnology

Ixaka

Joe Dupere

George O'Rourke

Nick Robbins-Cherry

Gilbert Wagener

Christian Hoyer Millar

Roxana Tundrea

Géraldine SARAGOUSSI

Victoria García

Eva López

Karen Miller

Sadia L’Baouch

The Scientific Research and Development team at Ixaka focuses on advancing the company's proprietary cell and gene therapy technologies. This team conducts cutting-edge research to enhance the therapeutic power of cells, develop targeted nanoparticles, and refine methods for modifying cells within the body. Their efforts support the treatment of serious diseases, including cancer, cardiovascular, neurological, and ocular disorders, as well as genetic conditions. Key areas of expertise within the team include chemistry, biology, polymer science, microfluidics, analytical development, and manufacturing processes.

Scientific Research and Development

Leadership Team

Quality Control and Assurance Team

Scientific Research and Development

About

Team members

Other teams at Ixaka

Leadership Team

Quality Control and Assurance Team